View Older Stories View More Recent Stories

Jan 2, 2020 07:58AM Intrexon (XON) Appoints Helen Sabzevari, PhD, as New President and CEO, to Change Name, Sell Non-healthcare Assets
Jan 2, 2020 07:55AM Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus
Nov 18, 2019 07:35AM Intrexon (XON) Subsidiary, Triple-Gene LLC, Reports Prelim. Ph. 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure
Nov 18, 2019 07:30AM Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
Nov 12, 2019 07:30AM Intrexon Reports Third Quarter 2019 Financial Results
Nov 7, 2019 07:52AM UPDATE: Intrexon (XON) Subsidiary Triple-Gene LLC Reports Complete Enrollment & Dosing in Ph. 1 Trial of INXN-4001
Nov 7, 2019 07:30AM Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
Nov 4, 2019 04:05PM Intrexon to Announce Third Quarter Financial Results on November 12th
Sep 26, 2019 07:30AM David H. Witte to lead MBP Titan LLC
Sep 24, 2019 04:00AM Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet Production
Sep 24, 2019 04:00AM Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet Production
Aug 19, 2019 07:31AM Intrexon (XON) Subsidiary ActoBio Therapeutics Grantef IND Green Light for New Antigen-Specific Immunotherapy Study
Aug 19, 2019 07:30AM ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
Aug 14, 2019 04:45PM Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
Aug 8, 2019 05:15PM Intrexon Reports Second Quarter and First Half 2019 Financial Results
Aug 5, 2019 07:41AM Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosing in Phase 1 Study of PRGN-3005 UltraCAR-T
Aug 5, 2019 07:30AM Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Aug 1, 2019 07:30AM Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th
Jul 1, 2019 07:34AM Intrexon (XON) Subsidiary ActoBio Therapeutics Inc. Advances AG019 to Next Stage of Phase Ib/IIa Clinical Study
Jul 1, 2019 07:30AM ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
Jun 26, 2019 07:34AM Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T
Jun 26, 2019 07:30AM Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
Jun 18, 2019 09:07AM Intrexon (XON) and Surterra Wellness announce exclusive global licensing agreement
Jun 18, 2019 09:05AM Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
Jun 13, 2019 07:30AM Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
Jun 3, 2019 08:30AM Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology
Jun 3, 2019 07:30AM Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce
May 29, 2019 08:08AM Fibrocell Science (FCSC) Granted FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for Treatment of RDEB
May 29, 2019 08:00AM Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
May 29, 2019 08:00AM Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
May 28, 2019 07:30AM Intrexon to Participate in 2019 BIO International Convention
May 15, 2019 07:30AM Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
May 13, 2019 07:30AM Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
May 9, 2019 04:10PM Intrexon Reports First Quarter 2019 Financial Results
May 2, 2019 04:05PM Intrexon to Release First Quarter 2019 Financial Results on May 9th
Apr 29, 2019 07:30AM Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting
Apr 25, 2019 04:05PM Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland
Apr 16, 2019 07:30AM Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
Apr 15, 2019 06:32AM Fibrocell Science (FCSC) Announces Pact with Castle Creek Pharma to Develop and Commercialize FCX-007 Gene Therapy
Apr 15, 2019 06:30AM Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
Apr 15, 2019 06:30AM Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
Apr 10, 2019 07:30AM Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference
Apr 9, 2019 07:30AM Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development
Apr 3, 2019 08:00AM Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
Apr 3, 2019 07:30AM Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management
Mar 27, 2019 07:32AM Fibrocell Science (FCSC) Reports Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
Mar 27, 2019 07:30AM Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
Mar 20, 2019 08:00AM Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
Mar 4, 2019 07:30AM Intrexon and Surterra Wellness to Collaborate on Botticelli™ Next Generation Plant Propagation for Cannabis Cultivation
Feb 28, 2019 04:15PM Intrexon Reports 2018 Fourth Quarter and Year End Financial Results
View More Recent Stories View Older Stories